Trends and variations in the epidemiology of meningococcal disease in Kuwait 1987–2013  by Husain, Entesar H. et al.
JT
e
i
E
M
a
b
M
R
S
h
1ournal of Infection and Public Health (2015) 8, 441—447
rends  and  variations  in  the
pidemiology  of  meningococcal  disease
n  Kuwait  1987—2013
ntesar  H.  Husaina,∗,  Mohammad  Barakatb,
osaab  Al-Salehb
Department  of  Pediatrics,  Faculty  of  Medicine,  Kuwait
Communicable  Diseases  Control  Unit,  Department  of  Public  Health,
inistry of  Health,  Kuwait
eceived  23  September  2014;  received  in  revised  form  23  December  2014;  accepted  23  January  2015
KEYWORDS
Neisseria  meningitidis;
Kuwait;
Meningococcal
conjugate  vaccine;
Meningococcal
polysaccharide  vaccine
Summary  The  introduction  of  Haemophilus  inﬂuenzae  type  b  (Hib)  conjugate
vaccine  and  conjugate  pneumococcal  vaccine  into  routine  childhood  vaccination
in  Kuwait  has  resulted  in  the  emergence  of  Neisseria  meningitidis  as  the  leading
cause  of  invasive  bacterial  infection  in  children.  Currently,  a  quadrivalent  ACYW-135
meningococcal  polysaccharide  vaccine  is  administered  as  part  of  routine  childhood
vaccination  in  Kuwait  at  the  age  of  2  years.  Conjugate  meningococcal  vaccines  have
been  shown  to  be  more  effective  in  preventing  meningococcal  infection  in  young
children.  The  objective  of  this  study  was  to  describe  the  epidemiology  of  meningo-
coccal  disease  (MD)  in  Kuwait  and  evaluate  the  need  for  conjugate  vaccine  in  routine
childhood  immunization.  We  have  reviewed  the  MD  surveillance  data  from  the  com-
municable  disease  unit,  Ministry  of  Health,  Kuwait  during  the  period  from  1987  to
2013.  The  analysis  included  microbiologically  conﬁrmed  cases  of  N.  meningitidis  in
the  blood  and  cerebrospinal  ﬂuid.  There  were  293  cases  of  conﬁrmed  MD  during
the  study  period.  Two  hundred  and  four  cases  (70%)  were  in  children  ≤14  years  of
age.  The  mean  incidence  rate  was  0.5/100,000  persons.  The  dominant  serogroups
were  W-135  and  B,  accounting  for  80  cases  (32%)  each.  Serogroup  B  accounted  for
69/204  (34%)  of  all  cases  in  children  ≤14  years  and  serogroup  A  accounted  for  36/89
40%  of  all  adult  cases.  There  were  three  outbreaks:  1987  (caused  by  serogroup  A),
1989  (caused  by  serogroup  W-135)  and  2002  (caused  by  serogroup  B).  The  mean  case
fatality  rate  was  13.5%.  In  conclusion,  despite  childhood  routine  vaccination  with
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ACYW-135  polysaccharide  vaccine,  infants  and  young  children  remain  at  high  risk
for  MD,  which  supports  the  introduction  of  conjugate  meningococcal  vaccine  to  the
routine  childhood  vaccination  schedule.
©  2015  King  Saud  Bin  Abdulaziz  University  for  Health  Sciences.  Published  by  Elsevier
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of identiﬁcation.  MD  is  deﬁned  as  the  isolation  of
N. meningitidis  from  the  blood  or cerebrospinal
ﬂuid. After  conﬁrmation  of  the  case,  a notiﬁcationLimited.  All  rights  reserv
Introduction
After  the  introduction  of  Haemophilus  inﬂuenzae
type b  (Hib)  conjugate  vaccine  and  pneumococ-
cal conjugate  vaccine  (PCV)  into  routine  childhood
vaccination programs,  Neisseria  meningitidis  has
become the  leading  bacterial  cause  of  meningitis
and sepsis  in  children  [1]. It  has  been  estimated  that
it causes  500,000  cases  and  50,000  deaths  annually
in children  less  than  5  years  of  age  worldwide  [2].
Kuwait is  situated  in  the  northern  edge  of  East-
ern Arabia  at  the  tip  of  the  Persian  Gulf.  Its  size
is 17,820  km2 with  a  population  of  4 million  as  of
2013. The  Ministry  of  Health  is  the  major  provider
of health  care  through  six  regional  health  care  dis-
tricts. The  private  health  sector  has  emerged  as  a
contributor  to  health  care  in  the  last  10  years.
The Hib  vaccine  was  introduced  in  Kuwait  in  1996
and  PCV  in  2006.  Additionally,  the  current  vaccina-
tion  schedule  includes  the  routine  administration  of
a quadrivalent  ACYW-135  polysaccharide  meningo-
coccal  vaccine  at  the  age  of  2 years.  We  have
previously reported  that  N.  meningitidis  is  the  most
common  cause  for  bacterial  meningitis  in  children
in Kuwait  [3].
Meningococcal  vaccination  recommendations  in
Kuwait have  changed  over  the  years  based  on  the
changing  epidemiology  of  meningococcal  infection
in the  country.  In  1987,  an  outbreak  of  N.  meningi-
tidis serogroup  A  led  to  a  recommendation  for  the
use of  a  bivalent  AC  meningococcal  polysaccharide
vaccine in  the  expanded  program  on  immunization
(EPI) for  children  4  years  of  age.  Additionally,  the
vaccination  program  of  pilgrims  going  to  Hajj  in
Saudi Arabia  was  started  in  the  same  year.  In  1997,
following  the  emergence  of  serogroup  W-135  in  the
country, the  quadrivalent  ACYW-135  meningococ-
cal polysaccharide  vaccine  replaced  the  bivalent  AC
polysaccharide  vaccine  in  the  EPI  schedule  for  chil-
dren at  4  years  of  age.  In  2008,  the  quadrivalent
ACYW-135  polysaccharide  vaccine  was  introduced
at 2  years  of  age  instead  of  4 years  as  part  of  the
EPI schedule.
f
n
aIn  addition  to  routine  vaccination  with  the
uadrivalent ACYW-135  meningococcal  polysaccha-
ide vaccine  in  all  children  at  the  age  of  2 years,  the
urrent  efforts  to  reduce  meningococcal  infection
n Kuwait  include  the  following  recommendations:
accination  of  all  contacts  of  cases  with  meningo-
occal disease  including  medical  and  paramedical
ersonnel, students  in  police  and  military  colleges
nd pilgrims  going  to  Hajj  and  Umrah  with  quadri-
alent ACYW-135  meningococcal  polysaccharide
accine [4]. In  addition,  a  bivalent  AC  meningococ-
al polysaccharide  vaccine  is  given  to  all  expatriate
aborers and  housemaids  [4].  No  conjugate  vac-
ine is  routinely  administered  to  any  of  the  groups
bove.
The  objective  of  this  study  was  to  describe
he epidemiology  of  meningococcal  disease  (MD)
n Kuwait  from  1987  to  2013  and  to  evaluate
he need  to  introduce  a conjugate  meningo-
occal vaccination  in  the  routine  vaccination
chedule.
ethods
urveillance
opulation-based  surveillance  for  MD  is  a  national
ctive  surveillance  in  Kuwait  that  was  started  in
987 by  the  Ministry  of  Health  (MOH).  Positive
ases with  N.  meningitidis  are  instantly  reported
o the  Preventive  Medicine  Department  in  each
ospital.  The  report  is  forwarded  from  all  six  gen-
ral hospitals  and  other  subspecialty  hospitals  in
uwait to  the  Department  of  Communicable  Dis-
ases Control  Unit  at  Ministry  of  Health  within  24  horm includes  patients’  demographic  data  including
ame, age,  nationality,  contact  tracing  information
nd outcome.  This  notiﬁcation  form  is  completed
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bpidemiology  of  meningococcal  disease  in  Kuwait  
y  the  preventive  medicine  doctors  at  the  hospital
nd is forwarded  to  the  Department  of  Communi-
able Diseases  Control  Unit.  We  excluded  cases  of
eningococcal  disease  based  on  clinical  suspicion
ithout  microbiological  evidence  of  N.  meningi-
idis. We  retrospectively  collected  all  available
ata on  this  active  surveillance  from  1987  to  2013
or further  analysis.  There  were  no  reports  from  the
eriod from  August  1990  to  February  1991,  as  the
ountry  was  under  the  Iraqi  invasion.
aboratory methods
ll  suspected  or  conﬁrmed  N.  meningitidis  isolates
ere transported  from  the  microbiology  laboratory
f the  hospital  to  the  central  public  health  labo-
atory  on  chocolate  agar  media  labeled  with  the
atient’s  name  and  identiﬁcation  number.  The  iso-
ate was  re-cultured  and  subjected  to  biochemical
esting for  conﬁrmation.  Serogrouping  was  con-
rmed  using  Bacto® N.  Meningitidis  antisera  [5].
solates were  classiﬁed  into  one  of  ﬁve  serogroups:
, B,  C,  X/Z,  Y  and  W-135.  Some  isolates  were  only
dentiﬁed  by  a  gram  stain  as  gram-negative  diplo-
occic,  but  the  culture  was  negative.  As  a result,
he isolate  serogroup  was  labeled  as  ‘undeﬁned’.
he serogroup  was  reported  to  the  Department  of
ommunicable  Diseases  Control  Unit  to  be  added
o the  notiﬁcation  form.  Currently,  there  is  no
olymerase  chain  reaction  (PCR)  testing  for  identiﬁ-
ation  or  serogrouping  of  N.  meningitidis  in  Kuwait.
tatistical analysis
ge  group,  monthly  distribution  of  cases,  meningo-
occal  serogroups,  crude  annual  disease  incidences
nd case  fatality  rate  were  calculated  for  all  MD
ases among  the  population  in  Kuwait  (citizens  and
esidents).  The  reported  ages  were  as  follows:  <1
ear, 1—4  years,  5—9  years,  10—14  years,  15—19
ears, 20—24  years,  25—34  years,  35—44  years  and
45 years.
All data  were  expressed  in  numbers  and  propor-
ions. Surveillance  data  were  computerized  using
xcel program  (Microsoft,  USA).
esults
 total  of  293  cases  of  meningococcal  disease
ere reported  from  1987  to  2013,  excluding  August
990—February  1991.  The  annual  frequency  and
ncidence  of  meningococcal  disease  in  Kuwait  per
00,000  populations  is  shown  in  Fig.  1.  The  mean
nnual incidence  is  0.5/100,000  populations.  The
t
(
c
yigure  1  Frequency  and  annual  incidence  of  meningo-
occal  disease  in  Kuwait  1987—2013.
eaks  in  the  graph  correspond  to  three  outbreaks
n 1987,  1989  and  2002.  The  disease  incidence  was
he lowest  and  most  steady  in  the  last  four  years
f surveillance  (2010—2013)  of  0.10—0.13/100,000
opulation.  The  highest  proportion  of  cases
ccurred between  the  months  of  December  and
pril in  210  cases  (71%).  The  reported  ages  were
s follows:  <1  year  61  (21%),  1—4  years  79  (27%),
—9 years  48  (16%),  10—14  years  17  (6%),  15—19
ears 10  (3%),  20—24  years  20  (7%),  25—34  years  30
10%), 35—44  years  18  (6%),  >45  years  10  (3%).
We excluded  41  isolates  that  were  undeﬁned
n the  subsequent  serogroup  analysis.  Out  of  252
dentiﬁed  isolates,  there  were  80  isolates  (32%)  for
oth serogroup  B  and  serogroup  W-135.  Serogroup
 accounted  for  74  isolates  (29%),  Y 10  isolates
4%), C  7  isolates  (3%)  and  X/Z  1  isolate  (0.4%).  The
ynamic  variation  of  serogroup  distribution  over
he period  of  the  study  is  shown  in  Fig.  2. Out
f the  293  isolates,  there  were  204  (70%)  isolates
rom children  ≤14  years  of  age  and  89  isolates
30%) in  adults  (>14  years  of  age).  Fig.  3 shows
he serogroup  distribution  in  relation  to  age.  During
he surveillance  period,  there  were  three  outbreaks
f MD  in  1987,  1989  and  2002.  Table  1  shows  the
erotype distribution  during  the  three  outbreaks.
he mean  case  fatality  rate  (CFR)  during  the  obser-
ation period  was  13.5%,  ranging  from  0%  during
996—1997,  2003—2004,  2007,  2010  and  2013  to  33%
n 1991  and  1998.
To  evaluate  the  trends  and  changes  in  the  epi-
emiology of  MD  in  relation  to  different  vaccination
rograms in  Kuwait,  we  divided  the  interval  of  the
tudy into  three  periods:  Period  (1),  in  which  the
ivalent  AC  polysaccharide  vaccine  was  adminis-
ered  at  the  age  of  4  years  (1987—1997);  period
2), in  which  the  quadrivalent  ACYW-135  polysac-
haride  vaccine  was  administered  at  the  age  of  4
ears (1998—2008);  and  period  (3),  in  which  the
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Figure  2  Meningococcal  serogroup  distribution  during  1987—2013.
tribu
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iFigure  3  Serogroup  dis
quadrivalent  ACYW-135  polysaccharide  vaccine  was
administered  at  the  age  of  2  years  (2009—2013).
The number  of  cases  of  MD  was  133  in  period  (1),
139 in  period  (2)  and  21  in  period  (3).  The  mean
incidence rate/100,000  persons  were  0.74  (range
0.3—1.4)  for  period  (1),  0.5  (0.2—1.1)  for  period
(2) and  0.13  (0.1—0.2)  for  period  (3).  The  decrease
of the  population  incidence  of  MD  after  the  switch
c
p
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Table  1  Neisseria  meningitidis  serogroup  distribution  duri
Year  Serogroup  (%)
A  (%)  B  (%)  C  (%)  
1987  23  (88)a 1  (4)  0  
1989  7  (26)  4  (15)  2  (7)  
2002  2  (8)  17  (65)a 0  
a Denotes the serogroup responsible for the outbreak.tion  in  relation  to  age.
o  the  quadrivalent  ACYW-135  was  associated  with
 P  value  of  <0.01.  There  was  an  82%  reduction
n the  incidence  of  MD  in  period  (3)  compared  to
eriod (1).  Children  up  to  14  years  of  age  were  dom-
nant in  periods  1  and  2  with  89  cases  (67%)  and  106
ases (76%),  while  adults  were  more  dominant  in
eriod 3 with  12  cases  (57%).  Serogroup  epidemiol-
gy varied  as  follows:  serogroup  A  was  dominant  in
ng  the  three  outbreaks  in  Kuwait.
W-135  (%)  Ungrouped  (%)  Total  #
0 2  (8)  26
12  (45)a 2  (7)  27
5 (19)  2  (8)  26
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tpidemiology  of  meningococcal  disease  in  Kuwait  
eriod  (1),  serogroup  B  in  period  (2)  and  serogroup
-135 in  period  (3).  The  mean  CFR  was  17.5%
or period  (1),  11.3%  for  period  (2)  and  12%  for
eriod (3).
iscussion
his  study  is  the  ﬁrst  to  present  this  compre-
ensive data  on  the  changing  epidemiology  of  MD
n Kuwait  since  the  establishment  of  the  active
urveillance 27  years  ago.  Ceyhan  et  al.  reported
n the  serogroups  and  CFR  in  Kuwait  as  part  of  their
eport  of  meningococcal  disease  in  the  Middle  East
nd North  Africa  [6]. Memish  and  Shibl  had  previ-
usly  published  part  of  this  surveillance  of 157  cases
uring the  period  of  1997—2009  [4].
There  was  an  82%  reduction  in  the  incidence
ate of  MD  in  Kuwait  over  the  last  27  years.  Sim-
lar reductions  in  the  number  of  cases  have  been
eported from  neighboring  Saudi  Arabia  from  338
ases in  2000  to  6  cases  in  2009  [4].  Other  near  Gulf
ountries  such  as  Oman,  Qatar  and  Bahrain  have
eported  a  low  incidence  of  <2/100,000  population
4].  This  reduction  in  Kuwait  can  be  explained  by
any factors:  strenuous  effort  by  the  Ministry  of
ealth to  prevent  the  importation  of  N.  meningi-
idis into  the  country  by  the  implementing  routine
accination in  children  and  vaccinating  pilgrims  and
aborers. Though  vaccination  seems  to  have  played
 major  effect  in  reducing  MD,  the  reduction  could
lso be  attributed  to  the  secular  trend  of  infection
ecause the  reduction  was  similar  among  all  major
erogroups  [6].  Another  factor  that  might  explain
his reported  drop  in  the  incidence  of  MD  espe-
ially in  the  last  four  years  of  the  surveillance  is
he liberal  use  of  oral  and  parenteral  antibiotics  by
octors before  appropriate  cultures  are  obtained.
Despite the  variation  in  serogroup  distribution
uring the  three  periods  of  the  study,  serogroups
 and  W-135  together  accounted  for  two-thirds  of
ll isolates.  This  dominance  differs  from  other  Gulf
ountries  where  serogroup  W-135  remains  the  dom-
nant serogroup  in  Saudi  Arabia,  Oman  and  Qatar
4].  It is  interesting  to  note  that  the  appearance
f W-135  in  Kuwait  was  ﬁrst  noted  during  the  out-
reak  of  1989,  which  was  before  the  outbreak  in
audi Arabia  in  the  year  2000  [7]. As  a  result  of  the
989 outbreak  and  the  persistence  of  serogroup  W-
35 in  the  subsequent  years,  the  Ministry  of  Health
n Kuwait  introduced  the  quadrivalent  ACYW-135
olysaccharide  vaccine  in  1997.  It  seems  that  this
arly introduction  of  the  quadrivalent  ACYW-135
olysaccharide  vaccine  prevented  a  similar  severe
-135  outbreak  reported  from  Saudi  Arabia  in
000.
j
i
c
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As  previously  discussed,  while  the  routine  use  of
he quadrivalent  ACYW-135  polysaccharide  vaccine
as successful  in  reducing  the  serogroup-related
urden  of MD  in  Kuwait,  serogroup  B  has  emerged
s a  major  cause  of  MD.  Serogroup  B  was  respon-
ible for  the  following  in  Kuwait:  MD  outbreak  in
002 accounted  for  30%  of  all  cases  of  MD  and  is
he main  cause  of  MD  in  children  up  to  14  years
39%). A  similar  emergence  of  serogroup  B  was
eported in  Saudi  Arabia  by  Khalil  and  Borrow  where
t constituted  60%  of  the  isolates  in  1998  [8]. Epi-
emics  of  serogroup  B  have  been  reported  in  other
ountries  such  as  the  United  States,  Canada  and
ew Zealand  [9—11]. Serogroup  B  dominance  in
uwait  might  be  related  to  routine  vaccination
ith the  quadrivalent  polysaccharide  vaccine  that
oes not  contain  serogroup  B.  With  reduction  of
he serogroups  A,  C,  W-135  and  Y,  the  relative
roportion of  serogroup  B  may  have  increased.  A
imilar explanation  was  given  when  the  number
f serogroup  B  cases  increased  playing  a signif-
cant role  in  children  <4  years  of  age  in  Saudi
rabia [12]. Many  studies  have  demonstrated  cap-
ular switching  of  N.  meningitidis  or  replacement  of
he serogroups  in  the  nasopharynx  following  elimi-
ation of  other  serogroups,  which  may  play  a  role
13,14].
Consistent  with  earlier  studies,  infants  and
oung children  represent  the  highest  risk  group  for
D. In  the  United  States,  the  reported  incidence
f meningococcal  disease  in  children  less  than  one
ear was  17%  between  years  1992  and  1997  with  the
eak incidence  in  infants  4—5  months  of  age  [15].
n our  population,  21%  of  MD  cases  were  in  children
1 year  of  age.  Although  the  vaccination  strate-
ies have  changed,  children  constituted  67%,  76%
nd 43%  for  periods  1,  2  and  3,  respectively,  of  all
ases of  MD.  This  high  proportion  of  MD  in  children
uggests that  the  current  vaccination  strategy  with
he quadrivalent  ACYW-135  polysaccharide  vaccine
s not  effective  in  preventing  MD  in  young  children.
 more  effective  vaccination  strategy  using  conju-
ate vaccine  in  the  routine  vaccination  schedule
s needed  in  Kuwait.  It  is  well  known  that  conju-
ate vaccines  in  children  less  than  2 years  of  age
re highly  immunogenic  and  induce  substantial  B-
ell memory  in  young  infants,  which  make  them
ore efﬁcacious  than  polysaccharide  vaccines  [16].
tudies have  shown  that  a quadrivalent  meningo-
occal conjugate  vaccine  Men  ACWY-CRM  used  in
nfants and  toddlers  was  immunogenic  and  well
olerated  [17,18]. The  UK  experience  with  the  con-
ugate meningococcal  serogroup  C  vaccine  resulted
n decreased  hospital  admissions  with  meningo-
occal diseases  in  children  from  34.5/100,000  in
999 to  12.4/100,000  in  2011[19].  In  their  position
[[
[
[
[
[
[
[
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paper  in  2011,  the  WHO  preferred  the  use  of  con-
jugate vaccine  over  polysaccharide  vaccines  due  to
their increased  immunogenicity,  particularly  in  chil-
dren <2  years  and  their  potential  herd  immunity
[20].
Regardless  the  signiﬁcant  reduction  in  the  inci-
dence  rate,  the  observed  case  fatality  rate  did  not
change signiﬁcantly.  The  mean  case  fatality  rate
of 13.5%  (11.3—17.5%  for  the  different  periods)  is
in the  range  of  what  has  been  reported  elsewhere
with invasive  meningococcal  disease.  Bilukha  and
Rosenstein  reported  a  case  fatality  rate  in  the  US
of 10—14%  [21].
Despite  the  various  insights  this  study  provided
about MD  in  Kuwait,  several  limitations  do  exist.
The main  limitation  is  its  retrospective  nature.  The
available  data  lacks  the  collection  of  speciﬁc  demo-
graphic  data  such  as  speciﬁc  ages  rather  than  the
age group,  the  type  of  infection  and  relation  of
mortality to  serogroup.  We  do  not  have  data  on  vac-
cinated  vs.  unvaccinated  individuals  and  the  type  of
vaccine to  evaluate  vaccine  efﬁcacy.
Conclusion
In conclusion,  MD  surveillance  data  in  Kuwait
provide valuable  information  about  the  different
trends of  MD.  There  has  been  a  dramatic  reduction
in the  incidence  of  MD  over  recent  years.  Infants
and young  children  remain  at  the  highest  risk,  which
calls for  the  administration  of  a  conjugate  vac-
cine. There  is  a  need  for  continuous  and  informative
surveillance and  monitoring  of  MD  to  help  in  further
public  health  measures  and  interventions.
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